Virgin Media O2 Selects Mavenir for its Open RAN Deployment
17.4.2023 10:00:00 EEST | Business Wire | Press release
Virgin Media O2 has selected Mavenir, the Network Software Provider building the future of networks with cloud-native solutions that run on any cloud, as its Open Radio Access Network (Open RAN) vendor. Mavenir will also be the prime integrator, providing its Open virtualised Radio Access Network (Open vRAN) solution for sites on Virgin Media O2’s network.
Virgin Media O2 will work with Mavenir to roll out a scalable Open vRAN solution as part of its network evolution plans and adopt a more flexible and cloud-native architecture.
Mavenir’s Open vRAN solution is built from the ground up to be cloud-native, with fully containerised microservices allowing it to be deployed easily on any cloud. Mavenir’s Open vRAN O-RAN compliant solution works on open interfaces supporting O-RAN Split 7.2x and Split 2.
It further disaggregates into Distributed Unit (DU) and Centralised Unit (CU). These entities work as containerised network functions running on Commercial Off the Shelf (COTS) hardware containing Intel processors.
Designed to support multiple Fronthaul splits simultaneously, the vRAN solution provides a vendor-agnostic and future-proof architecture, leveraging Virgin Media O2’s network infrastructure assets.
Mavenir’s Open RAN system will consist of fully virtualised L1, L2 vRAN SW and will operate on Intel Xeon Scalable Processors, along with Intel vRAN Accelerator ACC100 and Intel 800 series Ethernet adapters. The delivery will also feature Mavenir’s OpenBeam™ Radios including massive MIMO, 3rd party O-RAN based Radio Units (O-RU) for open Fronthaul, network monitoring and optimisation.
Jeanie York, Chief Technology Officer at Virgin Media O2, said: “Through digitalising our networks, we’re seamlessly integrating our infrastructure to get more value from our existing assets. Extending our collaboration with Mavenir to the RAN for the first time will help us establish a future-proof Open vRAN architecture, unlocking the benefits of a multi-vendor open interface while allowing us to rapidly benefit from an end-to-end network solution.”
Pardeep Kohli, President and CEO at Mavenir, said: “Mavenir’s Open vRAN cloud-native approach presents new pathways for automated networks to deliver on the use cases and data demands of today and beyond - driving network elasticity, flexibility and best-in-class automation. The Mavenir OpenBeam radio portfolio fully complements Virgin Media O2’s full spectrum requirements and we look forward to playing an active role in unlocking network automation and openness in the RAN.”
Cristina Rodriguez, Vice President Network and Edge Group at Intel, said: “Open and virtualised RAN represents the future: a flexible and scalable software-defined network. Intel is pleased to collaborate with and be part of the Virgin Media O2 technology journey with Mavenir. Together we are delivering innovation, performance, and we are working towards more sustainable networks.”
Notes to Editors
About Virgin Media O2
Virgin Media O2 launched on 1 June 2021, combining the UK’s largest and most reliable mobile network with a broadband network offering the fastest widely-available broadband speeds. It is a customer-first organisation that brings a range of connectivity services together in one place with a clear mission: to upgrade the nation. Virgin Media O2 is the corporate brand of the 50:50 joint venture between Liberty Global and Telefónica SA, and one of the UK’s largest businesses. The company has 47 million UK connections across broadband, mobile, TV and home phone. Its own fixed network currently passes 16.1 million premises alongside a mobile network that covers 99% of the nation’s population with 4G, and more than 1,600 towns and cities with 5G services targeting 50% population coverage in 2023.
About Mavenir
Mavenir is building the future of networks and pioneering advanced technology, focusing on the vision of a single, software-based automated network that runs on any cloud. As the industry's only end-to-end, cloud-native network software provider, Mavenir is focused on transforming the way the world connects, accelerating software network transformation for 250+ Communications Service Providers and Enterprises in over 120 countries, which serve more than 50% of the world’s subscribers. www.mavenir.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230316005006/en/
Contact information
Mavenir PR Contacts:
PR@mavenir.com
Maryvonne Tubb (US)
Emmanuela Spiteri (EMEA)
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 10:10:00 EEST | Press release
LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The
Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 10:00:00 EEST | Press release
Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 years, she has led global teams to achieve a 100% success rate from Phase 3 development through to FDA approval for multiple programs spanning oncology, immunology and respiratory medicine. In addition, she raised funds of around $400M as founder and CEO. Across her career she has contributed to 20 drug approvals, engaging
TOHKnet and Adtran conduct Japan’s first 50G PON trial on a live network4.8.2026 10:00:00 EEST | Press release
Adtran today announced that TOHKnet has completed Japan’s first live network trial demonstrating the coexistence of 50G PON, XGS-PON and EPON on a single fiber. Conducted in Sendai using Adtran’s SDX 6400 Series OLT, the demo showed how the platform enables three generations of PON technology to operate together in a live service environment. The results highlight a realistic path for operators to introduce 50G PON capacity while maintaining continuity for existing services, maximizing the value of deployed fiber assets and reducing the complexity and disruption typically associated with network upgrades. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260803353435/en/ Adtran’s SDX 6400 Series is helping TOHKnet demonstrate how Japan’s operators can migrate to 50G PON without disrupting existing PON services. “As demand for digital services continues to grow, this trial is a key milestone for the future of fiber access in Jap
“HATSUNE MIKU LIGHTS TOKYO” Debuts on July 254.8.2026 10:00:00 EEST | Press release
The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260802298570/en/ © Crypton Future Media, INC. On Saturday, July 25, "HATSUNE MIKU LIGHTS TOKYO", featuring the globally beloved virtual singer Hatsune Miku, held its first screening. The work brings the world of the popular song “M@GICAL☆CURE! LOVE ♥ SHOT!” to life across the entire façade of the Tokyo Metropolitan Government Building. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.55 million. As one of Tokyo’s emerging landmark attractions, the project continues to captivate audiences through its
Evexta Bio Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate Rupitasertib in Combination with a Selective Estrogen Receptor Degrader in Advanced / Metastatic Breast Cancer4.8.2026 10:00:00 EEST | Press release
Evexta Bio S.A., a precision oncology company, founded by Truffle Capital (founder of Abivax and Carvolix), and focused on the discovery and development of targeted therapies, today announced a clinical collaboration and supply agreement with plans to initiate a Phase 1b study combining its lead investigational compound, rupitasertib, with Roche’s investigational compound giredestrant, a selective estrogen receptor degrader (SERD), for the treatment of ER+, HER2-, ESR1-mutated advanced / metastatic breast cancer. Rupitasertib, is a first-in-class oral dual-node PI3K/AKT/mTOR (PAM) pathway inhibitor, which selectively inhibits S6K and AKT1/3. Rupitasertib was purposefully and rationally designed to target S6K for potent PAM inhibition and AKT1/3 to block the AKT compensatory feedback loop, while sparing AKT2 to avoid hyperglycemia, which we believe will lead to a superior efficacy and safety profile compared to other PAM pathway inhibitors. Under the terms of the agreement, Roche will s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
